Graffinity | A Business Unit of Santhera Therapeutics AG
HomeAbout usTechnologyBusinessMediaContactEventsDirections
> Overview > Partners > Timelines  > Benefit
 
Business | Overview
 
  Technology Access for our Customers
Graffinity offers numerous benefits to its customers on a straightforward basis with no downstream obligations.

In the first step the customer provides target protein to Graffinity. Graffinity then  performs SPR imaging based fragment screening with the drug target. Subsequently, the resulting data are used for a comprehensive SAR analysis which will be delivered  three-months after receipt of the target protein by Graffinity. As the key result of a project Graffinity finally delivers an agreed upon number of hit compounds to the customer for secondary assays.

Graffinity´s process delivers
• Window to novel, diverse chemistry
• Fragments and low affinity binders build the basis for novelty
• Novel binding modes can be characterized early
• Fastest read on druggability of targets
• Earliest look at SAR that is technically possible
• Technology and process scalable to any number of targets

Partnering contact:
Mathias U. S. Woker
738 Main Street, Suite 390
Waltham, MA 02451-0616, USA
Phone: +1 (0) 401 301 1086
E-Mail:Contact Mathias Woker

  Search using keywords  
 
  Print this page Print
 
Target History
• Various metabolic enzymes
• Kinases
(full length, catalytic domains)
• Proteases
• Protein-protein interaction targets
• Esterases
• Nuclear hormone receptors
•  Total more than 85 targets successfully tested since 2003.
 
 
 
Pictures | Impressions
Pictures from Graffinity
 
 
 
  Printer Print this page
 
Home | About Us | Technology | Business | Media | Contact | Events | Directions
Site Information
© 2004-2010 Graffinity
All rights reserved. | Top of page